To evaluate the diagnostic value of a combined strategy using the urine lipoarabinomannan (LAM) antigen assay and interferon-gamma release assay (IGRA) for active tuberculosis (TB), and to explore its potential as a non-invasive, sputum-independent diagnostic method for clinical application. This evidence concerns the gene IFNG and tuberculosis.